Format

Send to

Choose Destination
Expert Rev Vaccines. 2015;14(10):1331-46. doi: 10.1586/14760584.2015.1078732. Epub 2015 Sep 7.

Efficacy and effectiveness of live attenuated influenza vaccine in school-age children.

Author information

1
a 1 MedImmune, Gaithersburg, MD, USA.
2
b 2 AstraZeneca, Gaithersburg, MD, USA.
3
c 3 Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA.

Abstract

Evidence of high efficacy of live attenuated influenza vaccine (LAIV) from randomized controlled trials is strong for children 2-6 years of age, but fewer data exist for older school-age children. We reviewed the published data on efficacy and effectiveness of LAIV in children ≥5 years. QUOSA (Elsevier database) was searched for articles published from January 1990 to June 2014 that included 'FluMist', 'LAIV', 'CAIV', 'cold adapted influenza vaccine', 'live attenuated influenza vaccine', 'live attenuated cold adapted' or 'flu mist'. Studies evaluated included randomized controlled trials, effectiveness and indirect protection studies. This review demonstrates that LAIV has considerable efficacy and effectiveness in school-age children.

KEYWORDS:

effectiveness; efficacy; influenza vaccine; live attenuated influenza vaccine; school-age children

PMID:
26372891
DOI:
10.1586/14760584.2015.1078732
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center